<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04105270</url>
  </required_header>
  <id_info>
    <org_study_id>2019LS010</org_study_id>
    <nct_id>NCT04105270</nct_id>
  </id_info>
  <brief_title>P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC</brief_title>
  <official_title>A Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) or Durvalumab (MEDI4736) + Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, two arm, parallel-group, non-randomized, open label trial of oral
      restorative microbiota therapy (RMT) combined with intravenous (IV) durvalumab (MEDI4736) or
      durvalumab (MEDI4736) plus chemotherapy in patients with advanced or metastatic
      adenocarcinoma non-small cell lung cancer (NSCLC) with high or low programmed cell death
      ligand 1 (PD-L1) tumor cell (TC) expression respectively.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">January 2028</completion_date>
  <primary_completion_date type="Anticipated">January 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) (RECIST 1.1)</measure>
    <time_frame>2 Years</time_frame>
    <description>Objective response rate (ORR) of treatment with restorative microbiota therapy (RMT) in combination with durvalumab or durvalumab + chemotherapy as assessed by response evaluation criteria in solid tumors (RECIST 1.1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of RMT</measure>
    <time_frame>2 Years</time_frame>
    <description>Safety and tolerability of RMT in combination with durvalumab or durvalumab + chemotherapy as assessed by the incidence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) (RECIST 1.1)</measure>
    <time_frame>3 Years</time_frame>
    <description>Incidence of PFS using RECIST 1.1 in each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 Years</time_frame>
    <description>Incidence of OS using RECIST 1.1 in each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>2 Years</time_frame>
    <description>DOR of treatment with RMT in each treatment arm per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune mediated Adverse Events imAE</measure>
    <time_frame>2 Years</time_frame>
    <description>Rate of immune mediated adverse events (imAE) in each treatment arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) (iRECIST)</measure>
    <time_frame>2 Years</time_frame>
    <description>ORR using immune response evaluation criteria in solid tumors (iRECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) (iRECIST)</measure>
    <time_frame>3 Years</time_frame>
    <description>PFS using immune response evaluation criteria in solid tumors (iRECIST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QoL)</measure>
    <time_frame>2 Years</time_frame>
    <description>Difference in health-related quality of life (QoL) using European organization for research and treatment of cancer quality of life questionnaire (EORTC QLQ-30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QoL)</measure>
    <time_frame>2 Years</time_frame>
    <description>Difference in health-related quality of life (QoL) using lung cancer module (LC-13)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Adenocarcinoma of Lung</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A: Oral Restorative Microbiota Therapy (RMT) Capsules</intervention_name>
    <description>Arm A: Patients with PD-L1 TC expression (≥25%) will receive sixteen doses of oral RMT capsules (weekly</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>RMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: Oral Restorative Microbiota Therapy (RMT) Capsules</intervention_name>
    <description>Arm B: Patients with PD-L1 TC (&lt;25%) will receive sixteen doses of oral RMT capsules (weekly)</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>RMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A: Durvalumab 1500 mg IV</intervention_name>
    <description>Arm A: Patients with PD-L1 TC expression (≥25%) receive durvalumab 1500 mg IV every 4 weeks (Q4W) until disease progression or for a maximum of two years from the 1st dose of durvalumab</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: Durvalumab 1500 mg IV</intervention_name>
    <description>Arm B: Patients with PD-L1 TC (&lt;25%) receive durvalumab 1500 mg IV every 3 weeks (Q3W) for 4 cycles followed by durvalumab maintenance 1500 mg IV Q3W until disease progression or for a maximum of two years from the 1st dose of durvalumab</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B: Cisplatin/pemetrexed or Carboplatin/pemetrexed</intervention_name>
    <description>Arm B: Patients with PD-L1 TC (&lt;25%) receive cisplatin/pemetrexed or carboplatin/pemetrexed given every 3 weeks (Q3W) for 4 cycles followed by pemetrexed maintenance given Q3W</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the lung that is
             unresectable stage IIIB/C or stage IV, does not have an EGFR sensitizing (activating)
             mutation or ALK or ROS1 translocation

          -  Measurable disease based on RECIST 1.1

          -  Body weight of &gt;30kg

          -  Prior chemotherapy or immunotherapy as adjuvant therapy for lung cancer is permitted
             as long as it has been &gt;6 months from last dose at the time of enrollment. Local
             treatment of isolated lesions, excluding target lesions, for palliative intent is
             acceptable (e.g. by local surgery or radiotherapy). Prior systemic therapy for
             advanced/metastatic NSCLC makes the patient ineligible for this study.

          -  Patients with treated brain metastasis are eligible as long as they have stable
             symptoms, are more than 2 weeks from completion of therapy, and do not require more
             than 10mg of daily prednisone or equivalent.

          -  Tumor sample requirements

               -  Mandatory provision of an unstained, archived tumor tissue sample in a quantity
                  sufficient to allow for biomarker and genomic analysis. A minimum of 10 unstained
                  slides should be available for evaluation.

               -  Known PD-L1 TC expression status assayed by Ventana SP263. Patients who have
                  known PDL-1 as assayed by PharmDx 22C3 assay may be eligible; however, available
                  archival tissue will be used to assay with Ventana SP263 test.

          -  Evidence of post-menopausal status, or negative urine or serum pregnancy test for
             female pre-menopausal patients. Women will be considered postmenopausal if they have
             amenorrhea for 12 months without an alternative medical explanation.

        The following age-specific requirements apply:

          -  Women &lt;50 years old would be considered postmenopausal if they have amenorrhea for 12
             months or more following cessation of exogenous hormonal treatments and with
             luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal
             range

          -  Women ≥50 years of age would be considered postmenopausal if they have amenorrhea for
             12 months or more following cessation of all exogenous hormonal treatments,
             radiation-induced oophorectomy with last menses &gt;1 year ago, chemotherapy-induced
             menopause with &gt;1-year interval since last menses, or surgical sterilization
             (bilateral oophorectomy or hysterectomy)

             - Adequate organ function within 14 days of study enrollment defined as:

          -  Hemoglobin ≥ 9.0 g/dL

          -  Absolute neutrophil count ≥1,500/mcL

          -  Platelets ≥ 100,000/mcL

          -  Total bilirubin ≤1.5x upper limit of normal (ULN) - this will not apply to patients
             with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is
             predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will
             be allowed only in consultation with their physician.

          -  AST (SGOT) and ALT (SGPT) ≤2.5 x institutional ULN unless liver metastases are
             present, in which case it must be ≤5x ULN

          -  Measured creatinine clearance (CL) &gt;40 mL/min or calculated creatinine CL&gt;40 mL/min by
             the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection
             for determination of creatinine clearance:

               -  Expected life expectancy of at least 12 weeks in the opinion of the enrolling
                  investigator

               -  Women of childbearing potential and men with partners of child-bearing potential
                  must agree to use of contraception for the time of screening to the duration of
                  treatment and 3 months after the last dose of study drug - Refer to Section 6.4.3
                  Table 1.

               -  Provide voluntary written consent prior to the performance of any research
                  related tests or procedures.

        Exclusion Criteria:

          -  Dysphagia or inability to swallow medications

          -  Squamous cell, large cell, or NSCLC NOS (not otherwise specified) histology or mixed
             tumors

          -  Has untreated brain metastasis or active leptomeningeal carcinomatosis

          -  Has a known sensitivity to any component of therapeutic agents used in this study

          -  Receipt of any immunotherapy or investigational drug within 4 weeks prior to the first
             dose of study drug; and in the case of monoclonal antibodies 6 weeks prior to the
             first dose of study drug

          -  Had prior treatment with any other anti-PD-1, or PD-L1, including durvalumab or an
             anti-PD-L2 agent or an antibody or a small molecule targeting other immuno-regulatory
             receptors except as adjuvant therapy for NSCLC so long as it has been greater than six
             months since the last treatment

          -  Current or prior use of immunosuppressive medication within 28 days before the first
             dose of study drug, with the exceptions of intranasal and inhaled corticosteroids or
             systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
             prednisone, or an equivalent corticosteroid

          -  Recent major surgery within 4 weeks prior to entry into the study (excluding the
             placement of vascular access) that would prevent administration of study drug

          -  Active or prior documented autoimmune disease within the past 2 years requiring
             systemic treatment (i.e. with use of disease modifying agents, corticosteroids or
             immunosuppressive drugs). Patients with vitiligo, Grave's disease, or psoriasis not
             requiring systemic treatment (within the past 2 years) are not excluded. Replacement
             therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy
             for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic
             treatment.

          -  Active documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)
             who require immunosuppression or patients who exceed 10 mg/day of prednisone, or an
             equivalent corticosteroid are excluded

          -  History of primary immunodeficiency

          -  History of organ transplant that requires therapeutic immunosuppression

          -  Taking daily probiotics (patients with last probiotic &gt; 4weeks prior to first dose of
             RMT are eligible)

          -  History of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive) who
             are on anti-retroviral treatment for &lt; 6 months and absolute CD4 count&lt;500 (patients
             with HIV not meeting these criteria are eligible)

          -  Has known active Hepatitis B or C. Active Hepatitis B is defined as a known positive
             HBsAg, and positive hepatitis B virus quantification assay (patients with history of
             Hepatitis B who have seroconversion i.e. Hepatitis B core antibody positive and
             Hepatitis B surface antibody positive are eligible). Active Hepatitis C is defined by
             a known positive Hep C Ab result and positive quantitative HCV RNA results (Patients
             with Hepatitis C who are on anti-viral suppressive therapy and negative quantitative
             HCV RNA results are eligible)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active
             bleeding diatheses

          -  Myocardial infarction or stroke within 3 months prior to enrollment

          -  History of systolic or diastolic heart failure with New York Heart Association (NYHA)
             class III or IV symptoms (refer to Appendix II)

          -  Has active or prior history of (non-infectious) pneumonitis that required steroids or
             patients with interstitial lung disease

          -  Psychiatric illness/social situations that would limit compliance with study
             requirements or compromise the ability of the patient to give written informed consent

          -  Known history of active tuberculosis. Patients with prior history of latent TB could
             be included if they have been treated previously with isoniazid.

          -  Patients who are on chronic systemic antibiotic therapy (antibiotics for ≥60
             consecutive days within 12 weeks of enrollment). Patients who receive systemic
             antibiotics between enrollment and start of RMT are eligible

          -  Receipt of live attenuated vaccination within 30 days prior to study entry or within
             30 days of receiving RMT

          -  History of another primary malignancy (excluding non-melanoma skin cancer) within 5
             years prior to starting RMT, except if the patient has undergone potentially curative
             therapy with no evidence of disease recurrence for 5 years since initiation of that
             therapy

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the study drug or interpretation of patient safety or study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manish Patel, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota, Division of Hematology, Oncology and Transplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manish Patel, DO</last_name>
    <phone>612-624-6940</phone>
    <email>patel069@umn.edu</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

